Compare KRT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRT | NMRA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.2M | 311.3M |
| IPO Year | 2019 | 2023 |
| Metric | KRT | NMRA |
|---|---|---|
| Price | $41.10 | $1.70 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $26.50 | $7.50 |
| AVG Volume (30 Days) | 118.7K | ★ 895.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | 4.70 | ★ 5.23 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $467,743,000.00 | N/A |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | $120.44 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $20.61 | $0.83 |
| 52 Week High | $41.38 | $3.65 |
| Indicator | KRT | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 87.21 | 51.64 |
| Support Level | $21.64 | $1.53 |
| Resistance Level | N/A | $1.72 |
| Average True Range (ATR) | 1.22 | 0.10 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 100.00 | 57.47 |
Karat Packaging Inc is a distributor and manufacturer of disposable foodservice products and related items, including containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, gloves, and janitorial supplies, available in plastic, paper, biopolymer-based, and other compostable forms. The Company focuses on environmentally friendly products and provides customized solutions including product development, design, printing, and logistics services. It serves customers through chains and distributors, retail, and e-commerce/online, and operates in the manufacturing and distribution of single-use food and beverage products, as well as specialty food and beverage products and restaurant and warehouse supplies.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.